These sets of experiments revealed that, while both trastuzumab and pertuzumab could inhibit tumor growth on their own in vivo, the combination resulted in an enhanced therapeutic outcome often not observed on in vitro tumor growth and independent of HER2 signaling blockade. The gene discussed is ERBB2; the disease is neoplasm.